---
title: "12 Health Care Stocks Moving In Friday's After-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292366801.md"
description: "During Friday's after-market session, several healthcare stocks experienced significant volatility. Q32 Bio surged 44.4% to $16.19, while China Pharma Holding rose 13.15%. Other gainers included Conmed, Aardvark Therapeutics, Eledon Pharmaceuticals, and Accuray. Conversely, Med Pharmaceuticals fell 7.9%, with declines also seen in Atea Pharmaceuticals, Gelteq, OKYO Pharma, Universe Pharmaceuticals, and Galmed Pharmaceuticals."
datetime: "2026-07-10T21:05:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292366801.md)
  - [en](https://longbridge.com/en/news/292366801.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292366801.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Friday's After-Market Session

### Gainers

-   **Q32 Bio** (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-market session. The company's market cap stands at $213.4 million.
-   **China Pharma Holding** (AMEX:CPHI) shares increased by 13.15% to $0.65. The market value of their outstanding shares is at $25.9 million.
-   **Conmed** (NYSE:CNMD) shares increased by 8.88% to $41.9. The market value of their outstanding shares is at $1.1 billion.
-   **Aardvark Therapeutics** (NASDAQ:AARD) shares increased by 8.79% to $8.27. The market value of their outstanding shares is at $109.0 million.
-   **Eledon Pharmaceuticals** (NASDAQ:ELDN) shares moved upwards by 5.23% to $4.05. The company's market cap stands at $318.7 million.
-   **Accuray** (NASDAQ:ARAY) shares moved upwards by 4.8% to $0.25. The company's market cap stands at $31.4 million.

### Losers

-   **InMed Pharmaceuticals** (NASDAQ:INM) shares fell 7.9% to $1.51 during Friday's after-market session. The company's market cap stands at $8.8 million.
-   **Atea Pharmaceuticals** (NASDAQ:AVIR) stock fell 6.81% to $4.65. The company's market cap stands at $392.9 million.
-   **Gelteq** (NASDAQ:GELS) shares decreased by 6.06% to $0.5. The market value of their outstanding shares is at $5.8 million.
-   **OKYO Pharma** (NASDAQ:OKYO) stock decreased by 5.33% to $1.6. The company's market cap stands at $88.1 million.
-   **Universe Pharmaceuticals** (NASDAQ:UPC) shares decreased by 5.32% to $4.99. The company's market cap stands at $3.4 million.
-   **Galmed Pharmaceuticals** (NASDAQ:GLMD) shares decreased by 5.02% to $0.53. The company's market cap stands at $4.3 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [OKYO.US](https://longbridge.com/en/quote/OKYO.US.md)
- [UPC.US](https://longbridge.com/en/quote/UPC.US.md)
- [AARD.US](https://longbridge.com/en/quote/AARD.US.md)
- [GELS.US](https://longbridge.com/en/quote/GELS.US.md)
- [QTTB.US](https://longbridge.com/en/quote/QTTB.US.md)
- [ELDN.US](https://longbridge.com/en/quote/ELDN.US.md)
- [AVIR.US](https://longbridge.com/en/quote/AVIR.US.md)
- [ARAY.US](https://longbridge.com/en/quote/ARAY.US.md)
- [CPHI.US](https://longbridge.com/en/quote/CPHI.US.md)
- [CNMD.US](https://longbridge.com/en/quote/CNMD.US.md)
- [GLMD.US](https://longbridge.com/en/quote/GLMD.US.md)
- [INM.US](https://longbridge.com/en/quote/INM.US.md)

## Related News & Research

- [QTTB: Phase II results support phase III advancement for a safe, effective alopecia areata therapy](https://longbridge.com/en/news/298366322.md)
- [Universe Pharmaceuticals fields shareholder questions ahead of Sept. 30 annual meeting](https://longbridge.com/en/news/297701139.md)
- [OKYO Pharma to Highlight Urcosimod Progress at Cantor Global Healthcare Conference](https://longbridge.com/en/news/298310507.md)
- [Galmed Pharmaceuticals Shareholders Approve All Proposals at September 3 AGM](https://longbridge.com/en/news/297967947.md)
- [Galmed Pharmaceuticals holds annual shareholder meeting](https://longbridge.com/en/news/297953499.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**